TYK MEDICINES-B (02410.HK): Chairman Wu Yusheng Buys Additional 635,000 H Shares for HKD 2.09 Million
NewTimeSpace News: On 10 September 2026, TYK Medicines, Inc. (stock code: 02410) announced that Dr. Wu Yusheng, Chairman, Executive Director and President, purchased 635,000 H shares on the open market between 8 and 10 September 2026, representing approximately 0.17% of the issued share capital, for approximately HKD 2.09 million from his own resources.
Dr. Wu may continue to purchase shares depending on market conditions, with further purchases expected not to exceed HKD 3.0 million in aggregate, and shares bought between 8 September and 7 October 2026 will be voluntarily locked up for six months from the purchase date. The company confirmed that its public float remains sufficient under the Listing Rules and that the purchases complied with the Model Code in Appendix C3.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- TYK MEDICINES-B (02410.HK): Chairman Wu Yusheng Increases Shareholding with Planned Purchases of up to HKD 2 Million, Shares to Be Locked Up for Six Months
- TYK MEDICINES-B (02410.HK): Dovatinib mesylate tablets (TY-9591) granted conditional approval as first-line treatment for EGFR-mutant NSCLC with CNS metastases
- TYK MEDICINES-B(02410.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 24.9 million, loss narrowed by 77.81% YoY
- TYK MEDICINES-B (02410.HK): Initiates Litigation over Disputed TY-9591 Cooperation Agreement and Takes Legal Proceedings against Sichuan Huayu
